BC Innovations | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BC Innovations | Sep 19, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Counts of F. nucleatum bacteria in tumor mucosae could help predict responses to oxaliplatin and Xeloda combination therapy in colorectal cancer patients. In 31 patients, high counts of F. nucleatum in tumor...
BC Week In Review | Mar 2, 2017
Clinical News

Pemetrexed RTD regulatory update

FDA accepted an NDA from Eagle for pemetrexed RTD as monotherapy to treat locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and in combination with cisplatin to treat mesothelioma. The PDUFA date is...
BC Week In Review | Jan 4, 2017
Clinical News

Pemetrexed RTD regulatory update

Eagle said it submitted an NDA to FDA for pemetrexed RTD to treat locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and mesothelioma in combination with cisplatin. The product is a ready-to-dilute, IV...
BC Innovations | Nov 30, 2016
Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting ARPC3 in combination with angiogenesis inhibitors could help treat metastatic colorectal cancer. In patients treated with Avastin bevacizumab, high levels of ARPC3 in...
BC Week In Review | Sep 5, 2016
Company News

Eli Lilly sales and marketing update

The U.K.’s NICE issued final guidance recommending the use of Alimta pemetrexed from Eli Lilly as a maintenance treatment for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose disease has...
BC Week In Review | Jul 25, 2016
Company News

Eli Lilly sales and marketing update

The U.K.’s NICE issued final draft guidance recommending Alimta pemetrexed from Eli Lilly as a maintenance treatment for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose disease has not progressed...
BC Extra | Jul 21, 2016
Company News

NICE now backs Alimta maintenance therapy

In a final draft guidance, the U.K.'s NICE recommended Alimta pemetrexed from Eli Lilly and Co. (NYSE:LLY) as a maintenance treatment for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose...
BC Innovations | Apr 7, 2016
Distillery Therapeutics

Therapeutics: Thymidylate synthetase (TYMS)

Cancer INDICATION: Liver cancer In vitro and mouse studies identified an oral phosphoramidate-based prodrug of the TYMS inhibitor floxuridine that could help treat hepatocellular carcinoma (HCC). Chemical synthesis of benzylamine phosphoramidate analogs of floxuridine followed...
BC Innovations | Mar 17, 2016
Distillery Techniques

Techniques: Human induced pluripotent stem (iPS) cell-derived models of gliomagenesis for drug screening

Disease models TECHNOLOGY: Cell models Genetically engineered human iPS cell-derived models of gliomagenesis could be used to screen therapies for brain cancer. The cell models were generated from two sets of human iPS cells by...
Items per page:
1 - 10 of 215